Article
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
Multiple sclerosis (Houndmills, Basingstoke, England) - 1 Apr 2019
Buck Dorothea, Andlauer Till Fm, Igl Wilmar, Wicklein Eva-Maria, Mühlau Mark, Weber Frank, Köchert Karl, Pohl Christoph, Arnason Barry, Comi Giancarlo, Cook Stuart, Filippi Massimo, Hartung Hans-Peter, Jeffery Douglas, Kappos Ludwig, Barkhof Frederik, Edan Gilles, Freedman Mark S, Montalbán Xavier, Müller-Myhsok Bertram, Hemmer Bernhard
Abstract excerpt
BACKGROUND: Treatment of multiple sclerosis (MS) with interferon β can lead to the development of antibodies directed against interferon β that interfere with treatment efficacy. Several observational studies have proposed different HLA alleles and genetic variants associated with the development of antibodies against interferon β. OBJECTIVE: To validate the proposed genetic markers and to identify new markers....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.